Please assess the completion status of the following clinical trial:

Trial Title: Carboplatin, Paclitaxel, Bevacizumab and Vorinostat for Patients With Advanced Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Advanced non-squamous NSCLC~* No prior chemotherapy for advanced disease~* ECOG performance status 0 or 1~* Measurable disease~* Life expectancy \> 3 months~* Normal bone marrow, renal and hepatic function~* Ability to take oral medications~* Willingness to sign informed consent~Exclusion Criteria:~* History of brain metastasis~* Evidence of thromboembolic phenomenon and treatment with anticoagulants~* Pregnancy~* Uncontrolled inter-current illness~* Prior therapy with Paclitaxel

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Phase I dose escalating scheme
- 2 (Type: EXPERIMENTAL): Phase 2 will evaluate the toxicities and safety profile of the 4-drug regimen.

Based on this trial design, predict the completion outcome and termination type (if applicable).